• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
  • PharmAkea Announces Successful Completion of Phase 1 Trial for PAT-1251 pharmaceutical-technology
    August 23, 2017
    PharmAkea announced that it has successfully completed a Phase 1 single and multiple ascending dose (SAD/MAD) clinical study with PAT-1251, its novel, small-molecule LOXL2 inhibitor being developed for the treatment of IPF and other fibrotic diseases.

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service